Pancreatic Cancer Research

ResearcherJichi Medical UniversityActive in the last 2 years

Joji Kitayama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5708-7130; OpenAlex author ID A5040731065, A5063705305. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 9

  1. Diagnostic Biomarkers for Pancreatic Ductal Adenocarcinoma Using Non-Targeted Metabolomic Analysis. Co-author DOI 10.3390/cancers18040684↗
  2. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  3. Metformin reshapes the tumor microenvironment and enhances prognosis in invasive pancreatic ductal adenocarcinoma with diabetes mellitus. Co-author DOI 10.21037/jgo-2025-457↗
  4. Combined Intraperitoneal Paclitaxel and Systemic Chemotherapy for Patients with Massive Malignant Ascites Secondary to Pancreatic Cancer: A Report of Two Patie… Co-author DOI 10.2169/internalmedicine.2191-23↗
  5. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Last author DOI 10.1002/jhbp.1085↗
  6. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  7. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  8. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  9. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Co-author DOI 10.1007/s10637-016-0369-0↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hironori Yamaguchi · 5 shared papers, 2016–2026 · strength 0.84
  2. Naohiro Sata · 3 shared papers, 2024–2026 · strength 0.67
  3. Sohei Satoi · 6 shared papers, 2016–2025 · strength 0.65
  4. So Yamaki · 5 shared papers, 2020–2025 · strength 0.60
  5. Tomohisa Yamamoto · 5 shared papers, 2020–2025 · strength 0.60
  6. Tsutomu Fujii · 5 shared papers, 2020–2025 · strength 0.60
  7. Daisuke Hashimoto · 4 shared papers, 2021–2025 · strength 0.51
  8. Yasuhiro Kodera · 4 shared papers, 2020–2025 · strength 0.48
  9. Fuyuhiko Motoi · 4 shared papers, 2020–2025 · strength 0.48
  10. Mitsugu Sekimoto · 3 shared papers, 2020–2022 · strength 0.31
  11. Satoshi Hirano · 3 shared papers, 2020–2022 · strength 0.31
  12. Masamichi Hayashi · 3 shared papers, 2020–2022 · strength 0.31
  13. Suguru Yamada · 3 shared papers, 2020–2022 · strength 0.31
  14. Michiaki Unno · 2 shared papers, 2022–2025 · strength 0.29
  15. Kenichi Aizawa · 1 shared paper, 2026 · strength 0.28
  16. Hirofumi Sonoda · 1 shared paper, 2026 · strength 0.28
  17. Rei Takahashi · 1 shared paper, 2025 · strength 0.20
  18. Masanobu Taguchi · 1 shared paper, 2025 · strength 0.20
  19. Yoshiyuki Meguro · 1 shared paper, 2024 · strength 0.19
  20. Fuminori Sonohara · 2 shared papers, 2020–2021 · strength 0.19
  21. Naminatsu Takahara · 2 shared papers, 2016–2022 · strength 0.17
  22. Hiroyuki Isayama · 2 shared papers, 2016–2022 · strength 0.17
  23. Yousuke Nakai · 2 shared papers, 2016–2022 · strength 0.17
  24. Yosuke Inoue · 1 shared paper, 2025 · strength 0.17
  25. Yuki Homma · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.